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Abstract: Primary cutaneous B-cell lymphomas are a heterogeneous group of mature B-cells neoplasms with 
tropism	for	the	skin,	whose	biology	and	clinical	course	differ	significantly	from	the	equivalent	nodal	lymphomas.	
The	most	indolent	forms	comprise	the	primary	cutaneous	marginal	zone	and	follicle	center	B-cell	lymphomas	that	
despite the excellent prognosis have cutaneous recurrences very commonly. The most aggressive forms include 
the	primary	cutaneous	large	B-cell	 lymphomas,	consisting	in	two	major	groups:	the	leg	type,	with	poor	prog-
nosis,	and	others,	the	latter	representing	a	heterogeneous	group	of	lymphomas	from	which	specific	entities	are	
supposed	to	be	individualized	over	time,	such	as	intravascular	large	B-cell	lymphomas.	Treatment	may	include	
surgical	excision,	radiotherapy,	antibiotics,	corticosteroids,	interferon,	monoclonal	antibodies	and	chemotherapy,	
depending on the type of lymphoma and on the type and location of the skin lesions. In subtypes with good prog-
nosis is contraindicated overtreatment and in those associated with a worse prognosis the recommended therapy 
relies	on	CHOP-like	regimens	associated	with	rituximab,	assisted	or	not	with	local	radiotherapy.	We	review	the	
primary	cutaneous	B-cell	lymphomas,	remembering	the	diagnostic	criteria,	differential	diagnosis,	classification,	
and prognostic factors and presenting the available therapies.
Keywords:	Antineoplastic	combined	chemotherapy	protocols;	Follicular	lymphoma;	Interferon-alpha;	Lympho-
ma,	B-Cell;	Lymphoma,	B-Cell,	marginal	zone;	Lymphoma,	large	B-cell;	Monoclonal	antibodies;	Radiotherapy;	
Pseudolymphoma; Skin neoplasms
INTRODUCTION
Primary	 cutaneous	 lymphomas	 (PCL)	 are	 the	
most	frequent	extra-nodal	lymphomas,	with	incidence	
around	10	cases	per	million	inhabitants	per	year,	from	
which	20-30%	are	primary	cutaneous	B-cell	 lympho-
mas	(PCBCL).1,2	Although	 its	physiopathology	 is	still	
poorly	understood,	the	origin	appears	to	be	multifac-
torial and its genesis probably involves chronic anti-
gen	stimulation,	such	as	that	associated	with	bacterial	
and	 viral	 infections.	 Skin	 lesions	 consist	 of	 patches,	
plaques,	 nodules	 or	 tumors,	 and	 may	 be	 single	 or	
multiple.	 Given	 the	 clinical	 suspicion,	 the	 diagnosis	
is	established	by	skin	biopsy,	through	histological	and	
cytological	 examinations,	 eventually	 complemented	
by	 immunohistochemical	 and	 immunophenotypic,	
cytogenetic and genotypic studies.3-8 The differential 
diagnosis includes mainly pseudolymphomas and 
primary	 cutaneous	 T-cell	 lymphomas	 (PCTCL),	 as	
well systemic B-cell lymphomas with cutaneous in-
volvement.3-8
Like	 other	 cutaneous	 lymphomas,	 PCBCL	 are	
categorized	according	to	the	classification	of	the	con-
sensus	 between	World	 Health	 Organization	 (WHO)	
and	 European	Organization	 for	 Research	 and	 Treat-
ment	 of	Cancer	 (EORTC),	 from	 2005,	 and	 the	WHO	
classification	of	cancers	of	the	hematopoietic	and	lym-
phoid	tissues,	last	updated	in	2008.9-11 The WHO-EO-
RTC	schema	includes	three	major	categories	of	PCBCL,	
which differ from the biological point of view and cor-
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respond to different clinical and laboratory features: 
a)	primary	cutaneous	marginal	zone	lymphoma	(PC-
MZL),	 originating	 from	 the	 mucosa-associated	 lym-
phoid	tissue	(MALT),	more	specifically	from	the	skin	
associated	 lymphoid	 tissue	 (SALT);	 b)	primary	 cuta-
neous	follicle	center	lymphoma	(PCFCL),	originating	
from	cutaneous	follicle	center	B-cells;	and	c)	primary	
cutaneous	large	B-cell	lymphoma	(PCLBCL),	in	which	
two	major	groups	are	individualized,	“leg	type”	and	
“others”,	the	latter	being	heterogeneous	(Chart	1).10
The clinical course of PCBCL is generally more 
indolent and the prognosis is usually more favorable 
than	that	of	their	nodal	counterparts,	despite	the	high	
rate of cutaneous recurrences.3-8 PCMZL	 and	 PCFCL	
types	have	an	excellent	prognosis,	with	5	year	survival	
rates	higher	than	90%	in	both	cases,	while	for	PCLB-
CL,	particularly	leg	type,	prognosis	is	more	reserved,	
with	5-years	survival	rate	lower	than	60%.	3-8
The available therapeutic modalities are diverse 
and	 include	 surgical	 excision,	 radiotherapy,	 cortico-
steroids,	antibiotics,	monoclonal	antibodies	and	inter-
feron,	as	well	as	monotherapy	or	polychemotherapy	
schemas. Treatment should be tailored according to 
the risk and selected based on the type of lymphoma 
and	on	the	clinical	stage,	as	well	as	on	the	characteris-
tics	of	the	patient	and	the	number,	type,	extent,	loca-
tion and distribution of the skin lesions.3-8
We	review	PCBCL,	remembering	their	classifica-
tion,	diagnostic	criteria,	differential	diagnosis	and	prog-
nostic	factors,	and	presenting	the	available	therapies.
EPIDEMIOLOGY
An	American	epidemiological	study	published	
in	2009,	based	on	analysis	of	3,884	cases	of	PCL	diag-
nosed	in	the	United	States	between	2001	and	2005,	re-
vealed	that	71%	were	PCTCL	(7.7	cases/	million	inhab-
itants/	year)	and	29%	were	PCBCL	(3.1	cases/	million	
inhabitants/	year).2 In	addition,	it	showed	that	the	inci-
dence of PCL is higher in men than in women (14.0 ver-
sus	8.2	cases/	million	inhabitants/	year,	with	a	male/
female	ratio	of	1.72).	Also,	 it’s	higher	in	blacks,	 inter-
mediate	 in	Hispanic	Caucasians	and	 lower	 in	Asians	
(11.5,	7.9	and	7.1	cases/	million	inhabitants/	year,	re-
spectively).	The	highest	 incidence	of	PCTCL	was	ob-
served	in	blacks,	while	the	highest	incidence	of	PCBCL	
was observed in non-Hispanic Caucasians (10.0 and 
3.5	cases/	million	inhabitants/	year,	respectively).	This	
study also showed an increased incidence of PCL in 
the	years	2001-2003,	compared	to	that	observed	in	the	
years 1980-1982 (14.3 and 5.0 cases/ million inhabi-
tants/	year,	respectively),	stabilizing	between	2004	and	
2005	(12.7	cases/	million	inhabitants/	year).2
PHYSIOPATHOLOGY
The physiopathology of PCBCL is only partial-
ly understood. It is believed that they begin as reac-
tive	inflammatory	lymphoproliferative	processes	and	
that lymphomagenesis occurs in successive steps. 
Hence there are “borderline cases” in which it is dif-
ficult	 to	distinguish	between	pseudolymphomas	 (re-
active	 lymphoid	 hyperplasias)	 and	 real	 lymphomas.	
The transition from a pre-neoplastic to a neoplastic 
condition seems to be determined by imbalance be-
tween	 cell	 proliferation	 and	 apoptosis,	 deregulation	
of	major	biochemical	pathways	for	intracellular	signal	
transmission,	cell	adhesion	and	migration,	as	well	as	
expression of oncogenes and/or inhibition of tumor 
suppressor genes.
Chronic antigenic stimulation and viral and 
bacterial	infections	appear	to	be	predisposing	factors,	
but studies to support these assumptions are scarce 
and,	in	most	cases,	the	etiologic	agent	is	not	known.12-17 
Regarding	 viral	 infections,	 an	 important	 role	 of	 the	
herpes	viruses,	such	as	Epstein	Barr	virus	(EBV)	and	
Human	Herpes	 Virus	 type	 8	 (HHV8),	 was	 noted	 in	
the	genesis	of	some	lymphomas,	particularly	in	those	
occurring	 in	 immunocompromised	 individuals,	 such	
as	in	patients	infected	with	human	immunodeficiency	
virus	 (HIV)	and	 in	 transplant	 recipients.12 Also	note-
worthy is the possible association between Hepatitis 
C	Virus	 (HCV)	 infection	 and	 PCBCL.13,14	Concerning 
bacteria,	 PCMZL	 have	 been	 associated	with	Borrelia 
burgdorferi	 infection,	although	the	subject	 is	still	con-
troversy.15-21
Cutaneous B-cell lymphomas have also been 
described	 in	 patients	 treated	 with	 methotrexate,	 in	
particular for rheumatoid arthritis.22 In many of these 
cases,	EBV	has	been	documented	in	B-cells	lymphoma	
and regression of lesions has occurred after discontin-
uation	 of	 the	drug,	 suggesting	 that	methotrexate	 in-
duced immunosuppression have had a decisive role in 
triggering the lymphoproliferation.22-25
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CharT 1: Classification	of	the	primary	cutaneous	
B-cell	lymphomas,	as	proposed	by	WHO	and	EORTC
1.	Primary	cutaneous	marginal	zone	lymphomas
2. Primary cutaneous follicle center cell lymphomas
3. Primary cutaneous large B-cell lymphomas
3.1.	Primary	cutaneous	large	B-cell	lymphomas,	leg	type
3.2.	Primary	cutaneous	large	B-cell	lymphomas,	other
3.2.1. Intravascular large B-cell lymphomas
3.2.2. Other primary cutaneous large B-cell lymphomas
Source:	Willemze	R	et	al,	200510
Abbreviations:	WHO,	World	Health	Organization;	 EORTC,	 European	Or-
ganization	for	Research	and	Treatment	of	Cancer
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DIAGNOSIS
Clinical manifestations
PCBCL	 manifest	 by	 patches,	 plaques	 and	
non-ulcerated	nodules	and/or	tumors,	single	or	mul-
tiple,	usually	with	firm	consistency.	Although	extracu-
taneous	 dissemination	may	 occur,	 in	most	 cases	 the	
disease	remains	localized	to	the	skin.3-8 Given the clini-
cal	suspicion,	the	diagnosis	is	established	by	perform-
ing	a	biopsy	of	 the	skin	 lesions,	 through	histological	
and	cytological	examinations,	complemented	by	phe-
notypic and genotypic studies.3-8
Histology and cytology
The pattern of cutaneous involvement by PC-
BCL	 differs	 from	 that	 observed	 in	 PCTCL,	 being	
characterized	 by	 a	 nodular	 or	 diffuse,	 often	 sharply	
demarcated,	non-epidermotropic	lymphoid	infiltrate,	
located	 predominantly	 in	 the	 dermis,	 and	 sparing	
the	sub-epidermal	“Grenz	zone”.26 From a cytological 
viewpoint,	neoplastic	B-cells	resemble	normal	B-cells	
that	give	rise	to	them,	i.e.	centrocytes	and	centroblasts	
in	 the	 case	 of	 PCFCL,	 monocytoid	 marginal	 zone	
B-cells	 and	 plasma	 cells	 in	 the	 case	 of	 PCMZL,	 and	
centroblasts,	 immunoblasts	 or	 anaplastic	 cells	 in	 the	
case of PCLBCL.
Immunohistochemistry and immunopheno-
typing
Immunohistochemistry for lymphoma charac-
terization	 should	 include	different	 types	of	markers:	
a)	 markers	 to	 demonstrate	 B-cell	 origin	 (e.g.	 CD19,	
CD20	 and	 CD79a);	 b)	 markers	 to	 characterize	 ex-
panded	B-cell	population	(e.g.,	CD5	and	CD10)	and	to	
evaluate clonality (immunoglobulin kappa and lamb-
da	light	chains);	as	well	as	c)	markers	to	characterize	
accompanying cells consisting of plasma cells (e.g. 
CD138),	T-cells	(e.g.	CD3,	CD4,	CD8),	and	follicle	den-
dritic	cells	(e.g.	CD21).
In	 general,	 B-cells	 stain	 positively	 for	 CD19,	
CD20,	CD79,	mu	(IgM)	or	gamma	(IgG)	immunoglob-
ulin	 (Ig)	heavy	chains,	and	kappa	or	 lambda	 Ig	 light	
chains,	 and	 they	are	negative	 for	T-cell	markers	 (i.e.,	
CD2,	CD3,	CD4,	CD7	and	CD8).	In	addition,	CD5	is	use-
ful to exclude secondary skin involvement by chronic 
lymphocytic leukemia/ small lymphocytic lymphoma 
(CLL/SLL)	and	mantle	cell	lymphoma	(MCL),	where-
as	CD10	may	be	positive	in	follicle	center	lymphoma,	
particularly in those from nodal origin.27
One	question	that	often	arises	is	the	differential	
diagnosis between PCLBCL-leg type and other PCL-
BCL,	particularly	PCFCL	with	diffuse	growth	pattern	
and	predominance	of	centroblasts.	In	this	regard,	it	is	
useful to assess the expression of other molecules in 
the	neoplastic	B-cells,	such	as	MUM1/IRF4	(Multiple	
Myeloma	 1	 /	 Interferon	 Regulatory	 Factor	 4),	 BCL2	
(B-Cell	Lymphoma	2),	BCL6	(B-Cell	Lymphoma	6)	and	
HGAL	(Human	Germinal	center-Associated	Lympho-
ma).	A	study	in	which	these	antigens	were	evaluated	
by immunohistochemistry showed that the combi-
nation	of	BCL6	with	HGAL	has	high	sensitivity	and	
specificity	 for	 the	diagnosis	of	PCFCL	whereas	posi-
tivity for BCL2 and MUM1/IRF4 favors the diagnosis 
of PCLBCL-leg type.28 Thus,	MUM1,	BCL2	and	BCL6	
molecules are useful for distinguishing PCLBCL-leg 
type	(BCL2+,	BCL6-/+,	MUM1+)	from	PCFCL	(BCL2-
/+,	 BCL6+,	 MUM1-)	 and	 PCMZL	 (BCL2+,	 BCL6-,	
MUM1-).
Genetics and cytogenetics
The study of molecular rearrangements of genes 
encoding	Ig	heavy	chains	(IGH)	is	useful	to	differen-
tiate	PCBCL	from	pseudolymphomas.	Until	 recently,	
cytogenetic studies had limited value in the diagnosis 
of	 PCBCL,	 since	 recurrent	 chromosomal	 and	molec-
ular alterations were unknown.23 In	 particular,	 most	
PCFCL	do	not	 express	 t(14,18)	 (q32,	 q21)	 that	 deter-
mines BCL2-JH rearrangement and features nodal FL. 
Likewise,	PCMZL	cells	do	not	have,	in	general,	the	cy-
togenetic	abnormalities	found	in	nodal	MZL.29
More recent studies performed by comparative 
genomic	hybridization	(CGH),	using	microarrays	and	
subsequently	 confirmed	 by	 fluorescence	 in	 situ	 hy-
bridization	 (FISH)	 enabled	 to	 detect	 a	 large	 number	
of	recurring	genetic	aberrations	in	PCLBCL-leg	type,	
and,	although	less	frequently,	in	PCFCL	with	predom-
inance	of	large	cells;	in	contrast,	they	are	rarely	found	
in	indolent	PCFCL	and	PCMZL.
One of the genes involved recurrently in PCLB-
CL-leg	type	is	CDKN2A	(cyclin-dependent	kinase	in-
hibitor	2A)	gene,	located	in	the	9p21	region,	which	of-
ten suffers deletion or inactivation in order to promote 
hypermetilation.30-32 This gene encodes for the protein 
p16	 (also	 known	 as	 INK4,	 inhibitor	 of	 kinase	 4),	 an	
inhibitor of cell proliferation pathway dependent on 
CDK4	(cyclin-dependent	kinase	4)	 (p26-INK4/CDK4	
axis),	 as	well	 as	 for	 the	 protein	 p14	 (also	 known	 as	
ARF,	 alternate	 open	 reading	 frame),	 which	 acts	 by	
stabilizing	the	p53	protein	(p14-ARF/p53	axis).	Such	
genetic aberrations result in instability/degradation 
of	p53	protein.	In	addition,	the	increase	in	CDK4	activ-
ity	determines	the	inactivation	of	Rb	(retinoblastoma)	
protein,	coded	by	the	RB1	gene	located	in	the	region	
13q14.2,	which	negatively	regulates	cell	cycle	progres-
sion	 (p26-INK4	 axis/Rb),	 resulting	 in	 increased	 cell	
proliferation.30-32 Other changes described as being re-
current	in	PCLBCL-leg	type	are	DNA	amplifications	in	
the	region	18q21.31-q21.33,	which	includes	BCL2	and	
MALT1	genes,	as	well	as	t(8,14)	(q24,q32).30,31
A	 study	 in	which	31	patients	with	PCBCL	 (19	
with	PCFCL	and	12	with	DLBCL-leg	type)	were	evalu-
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ated	using	CGH,	revealed	that	most	PCFCL	cases	have	
recurrent	DNA	amplifications	 at	 2p16.1	 region,	with	
amplification	of	c-REL	gene	(63%	of	the	cases),	and	de-
letions	in	region	14q32.33	(68%	of	the	cases).30 The same 
study showed that PCLBCL-leg type cases have recur-
rent	 DNA	 amplifications	 in	 region	 18q21.31-q21.33	
(67%	of	the	cases),	which	includes	BCL2	and	MALT1	
genes,	 and	 recurrent	homozygous	DNA	deletions	 in	
region	9p21.3	(42%	of	the	cases),	which	contains	CD-
KN2A,	CDKN2B	and	NSG-x	genes.	In	addition,	some	
patients	with	PCLBCL-leg	type	(17%)	have	a	complete	
hypermethylation	of	CDKN2A	gene	promoter.
Another	 study	 with	 a	 smaller	 number	 of	 pa-
tients	(4	with	PCMZL;	7	with	PCFCL	with	small	cells;	
4 with PCFCL with large cells; 6 with PCLBCL-leg 
type)	confirmed	the	existence	of	deletions	in	9p21	re-
gion,	 containing	CDKN2A	gene,	which	 encodes	 p16	
(INK4)	 and	 p14	 (ARF)	 proteins,	 in	 all	 PCLBCL-leg	
type,	and	deletions	in	1p36	region	in	all	PCFCL	with	
large cells. 31 Furthermore,	presence	of	t(8;14)	(q24,q32)	
was	demonstrated	by	FISH	in	2	of	6	(33%)	DLBCL-leg	
type	analyzed.31 
Finally,	a	study	in	which	changes	in	genes	cod-
ifying	 for	 p26,	 p14,	 p53	 and	 Rb	 were	 examined	 by	
FISH and immunohistochemistry in 22 patients with 
PCBCL	(9	with	PCFCL;	7	with	PCMZL;	6	with	PDL-
BCL-leg	type)	revealed	alterations	of	CDKN2A,	TP53	
and RB genes in most patients with DLBCL-leg type. 
These changes are exceptionally rare in PCFCL and 
PCMZL.32
Gene expression studies are useful to distin-
guish PCBCL subtypes.33,34	 Primary	 cutaneous	 MZL	
usually have a “plasma cell” pattern of gene expres-
sion,	 while	 PCFCL	 usually	 have	 overexpression	 of	
SPINK2	gene,	and	a	“germinal	center	B-cell”	pattern	
of gene expression.33,34	 In	 contrast,	 PCLBCL-leg	 type	
usually have an increased expression of genes in-
volved	 in	 cell	proliferation,	proto-oncogenes	 (PIM-1,	
MIP-2	and	c-MYC),	as	well	as	of	genes	encoding	tran-
scription	factors	(IRF4	and	OCT-2),	corresponding	to	
an “activated B-cell” pattern.34
DIFFERENTIAL DIAGNOSIS
Primary cutaneous T-cell lymphoma
In	general,	 the	 cytological	 and	histological	 as-
pects observed in PCBCL differ from that observed 
in PCTCL.23,26	 Histologically,	 the	 pattern	 of	 infiltra-
tion observed is described as being “ball-shaped” 
and	“non-epidermotropic”	 in	PCBCL,	and	“horizon-
tal”,	“disc-shaped”	and	epidermotropic	in	PCTCL.	In	
addition,	neoplastic	T-cells	 tend	to	have	an	 indented	
and	cerebriform	nucleus,	while	neoplastic	B-cells	may	
have	the	aspect	of	centrocytes,	centroblasts,	immuno-
blasts or plasmablasts. Regardless the morphological 
differences,	 the	 immunophenotypic	 characterization	
of neoplastic cells by immunohistochemistry and/or 
flow	cytometry	 is	critical	 to	distinguish	a	T-cell	 lym-
phoma	 (e.g.	CD2,	CD3,	CD4	and	CD8)	 from	a	B-cell	
lymphoma	(e.g.	CD19,	CD20	and	CD79).
Cutaneous pseudolymphoma
The differential diagnosis between a “pseudo-
lymphoma”	 (reactive	 lymphoid	 hyperplasia)	 and	 a	
PCBCL	(follicle	center	or	marginal	zone	type)	can	be	
very	difficult.26,35-37 Primary cutaneous B-cell lympho-
mas,	 like	 “pseudolymphomas”,	 may	 sometimes	 be	
manifested	by	skin	 lesions	 in	 insect	bite,	vaccination	
or	tattoo	sites.	From	the	histological	point	of	view,	in	
“pseudolymphomas” it is generally observed a nodu-
lar	infiltration	of	the	dermis	by	lymphoid	cells,	which	
can	form	germinal	centers,	together	with	macrophages	
with	 cytoplasm	 loaded	 with	 debris,	 with	 aspect	 of	
“starry	sky”.	T-cells,	plasma	cells	and	eosinophils	are	
usually more abundant at the periphery of the nodules 
and in the interfollicular regions. The demonstration 
of a balanced expression of kappa and lambda light 
chains	on	B	lymphocytes,	a	polyclonal	rearrangement	
of	 the	 IGH	genes	 and	 the	presence	 of	 an	 organized,	
round	 or	 oval-shaped,	 network	 of	 CD21+	 dendrit-
ic	 cells,	 favors	 the	diagnosis	of	 “pseudolymphoma”.	
Rather,	 an	 imbalance	 of	 kappa	 and	 lambda	 Ig	 light	
chain	expression,	a	clonal	rearrangement	of	IGH	genes	
and	the	presence	of	an	unstructured	network	of	CD21+	
dendritic cells favor the diagnosis of lymphoma.
In	our	experience,	like	the	experience	of	others,	
the	 immunophenotypic	 study	 by	 flow	 cytometry	 of	
the lymphoid cells derived from skin biopsy is useful 
in helping to distinguish between reactive lymphoid 
hyperplasia	and	cutaneous	B-cell	 lymphoma,	as	well	
as	to	identify	the	monoclonal	B-cells,	often	with	abnor-
mal immunophenotype.27,38
Primary cutaneous B-cell lymphoma subtypes
Clinical	manifestations	are	obviously	not	suffi-
cient	 to	make	 the	diagnosis	of	PCBCL,	but	 type	and	
location of lesions may give some indication. Primary 
cutaneous follicle center lymphoma manifests more 
frequently	 in	 head	 and	 neck	 regions,	 while	 PCMZL	
predominantly affects trunk and limbs. Presence of 
nodules and/or single or multiple tumors in the legs 
should	constitute	a	suspicion	of	PCLBCL-leg	type,	es-
pecially when the patient is an aged woman.39,40
The	 immunophenotypic	 profile	 of	 neoplastic	
B-cells,	documented	by	immunohistochemistry	and/
or	flow	cytometry,	 is	crucial	for	the	differential	diag-
nosis	(Chart	2).
Other B-cell lymphomas
Follicular lymphoma (FL): Skin involvement 
can	occur	 in	systemic	FL,	so	 it	 is	 important	 to	estab-
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lish the differential diagnosis.41 Head and neck are the 
most commonly affected regions in both cases. The 
positivity for CD10 and BCL2 and the presence of 
t(14,	18)	are	more	frequent	in	cases	of	secondary	skin	
involvement by systemic FL than in PCFCL. BCL6 is 
positive in both cases.41
Mantle cell lymphoma (MCL): Skin involve-
ment by MCL is rare and usually secondary.42 Histo-
pathological	 skin	 examination	 shows	 infiltration	 in	
the dermis and subcutaneous tissue by atypical lym-
phoid	cells	positive	for	CD20,	CD5,	CD43	and	cyclin	
D1,	but	negative	for	CD10	and	CD23.
B-cell chronic lymphocytic leukemia (B-CLL): 
Like	 MCL,	 B-CLL	 may	 also	 involve	 skin.43-45 B-CLL 
lymphocytes	are	CD5+,	but	different	from	what	hap-
pens	with	MCL,	they	are	also	CD23	and	CD200	posi-
tive,	and	do	not	express	cyclin	D1.
Waldenström’s macroglobulinemia: This dis-
ease	is	characterized	by	an	expansion	of	clonal	B-cells	
with	 plasmacytoid	 differentiation,	 which	 produces	
large	 amounts	 of	 IgM	 and	 infiltrates	 bone	 marrow,	
lymph nodes and spleen. Cutaneous manifestations 
are diverse and may consist of urticaria and purpuric 
rashes,	ulcers,	bullous	lesions	and	vasculitis.46,47
Plasma cell neoplasms: Cutaneous plasmacy-
tomas	can	be	primary	(no	extra-cutaneous	disease)	or	
secondary	and,	in	the	latter	case,	they	arise	in	patients	
with	 plasma	 cell	myeloma	 or	 plasma	 cell	 leukemia,	
and	rarely	may	be	the	first	clinical	manifestation	of	the	
disease.48 In	plasma	cell	myeloma,	hyperkeratotic	spic-
ules	can	be	observed,	preferably	in	the	face.49-51
Lymphomatoid granulomatosis: This is a rare 
extranodal	 B-cell	 lymphoproliferative	 disorder,	 sys-
temic,	 angiocentric	 and	 destructive,	 which	 involves	
various	organs	and	tissues,	especially	lungs,	nervous	
system and skin.52 It	associates	with	EBV	infection	and	
may progress to a large B-cell lymphoma.
Burkitt’s lymphoma: It’s an aggressive B-cell 
neoplasm that may secondarily involve the skin. In its 
endemic	form,	it	occurs	in	children	from	Central	Afri-
ca,	where	 in	most	cases	 it	associates	with	EBV	infec-
tion. Sporadic cases observed in Europe and the Unit-
ed	States	may	be	associated	or	not	 to	EBV	and	may	
occur	in	HIV	infected	patients.53
LABORATORY TESTS
In	PCBCL,	analytical	or	imaging	changes	attrib-
utable to lymphoma are not expected to occur at diag-
nosis.	However,	laboratory	tests	should	be	performed	
for	two	reasons:	to	confirm	that	it	is	a	PCBCL	and	not	a	
secondary skin involvement by a systemic lymphoma; 
and	to	exclude	associated	diseases,	as	it	may	be	crucial	
for therapeutic decisions.54
In	general,	it	is	advisable	to	perform	a	complete	
blood cell count with leukocyte differential and a bio-
chemical	study,	which	should	include	liver	and	kidney	
analysis,	 measurement	 of	 serum	 levels	 of	 beta2-mi-
croglobulin,	 an	 indicator	 of	 tumor	mass,	 and	 lactate	
dehydrogenase	(LDH),	an	indicator	of	tumor	lysis.	If	
leukemic blood involvement is suspected (lympho-
cytosis,	atypical	lymphocytes)	at	diagnosis	or	during	
disease	progression,	the	immunophenotypic	study	of	
peripheral blood lymphocytes should be performed.
Additional	tests	for	staging	include	chest	radi-
ography and abdominal ultrasound. In patients with 
PCLCBL	 and	 in	 cases	 with	 advanced	 skin	 disease,	
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CharT 2: Immunophenotypic characteristics of the neoplastic B-cells in primary cutaneous B-cell lymphomas
 CD19
 CD20 CD5 CD10 BCL-6 BCL-2 MUM1 FOXP1 
PCMZL +	 -	 -	 -	 +	(1)	 -	(3)	 -
PCFCL	 +	 -	 -/+	 +	 -/+	(2)	 -	 -/+
PCLBCL,leg	type	 +	 -	 -	 -/+	 ++	(1)	 +	 +
Abbreviations:	BCL-2,	B-cell	 lymphoma	2;	BCL-6,	B-cell	 lymphoma	6;	MUM1/IRF4,	Multiple	Myeloma	1	/	Interferon	Regulatory	Factor	4	protein;	FOXP1,	
Forkhead	Box	Protein	P1;	PCFCL,	primary	cutaneous	follicle	center	cell	lymphoma;	PCLBCL,	primary	cutaneous	large	B-cell	lymphomas,	leg	type;	PCMZL,	
primary	cutaneous	marginal	zone	lymphomas.
(1)	t(14;18)	negative;	(2)	t(14;18)	negative	and	BCL2	negative	in	the	majority	of	cases;	(3)	Plasma	cells	are	MUM1+.
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thoracic,	 abdominal	 and	 pelvic	 computed	 tomogra-
phy	(CT)	should	be	also	done.	A	bone	marrow	(BM)	
biopsy,	 preferentially	 complemented	 with	 lympho-
cyte	immunophenotyping	by	flow	cytometry,	is	man-
datory	 to	 exclude	 BM	 involvement;	 however,	 it	 can	
be dispensed in PCBCL with good prognosis (e.g. 
PCMZL),	with	 typical	 clinical	 presentation	 and	 lim-
ited	skin	 lesions.	 If	adenomegalies	are	present,	 these	
should	be	investigated,	preferably	with	excisional	bi-
opsy,	 in	 order	 to	 exclude	 extracutaneous	 lymphoma	
and/or nodal involvement by cutaneous lymphoma. 
Histopathological and immunohistochemical studies 
should	be	supplemented	by	flow	cytometry-based	im-
munophenotyping when possible.
BIOLOGICAL ENTITIES
At	least	three	entities	were	described,	which	dif-
fers from the biological point of view and in clinical 
and	laboratory	characteristics	(Chart	3).
Primary cutaneous marginal zone B-cell lym-
phomas
Primary	 cutaneous	 marginal	 zone	 B-cell	 lym-
phomas	(PCMZL)	are	extranodal	marginal	zone	B-cell	
lymphomas,	originating	from	MALT,	more	specifical-
ly	 from	SALT.	They	 represent	about	10%	of	all	PCL,	
showing indolent clinical behavior and excellent prog-
nosis,	with	survival	rate	in	5	years	exceeding	95%.55-60 
They	 can	develop	 from	 reactive	 lymphoid	 infiltrates	
and,	in	some	cases,	pathogenic	relationship	with	Bor-
relia burgdorferi infection has been suspected.12,14	Pri-
mary cutaneous immunocytoma and primary cutane-
ous	plasmacytoma	were	considered	PCMZL	variants.
Clinically,	PCMZL	usually	manifests	in	the	form	
of solitary or multiple erythematous or violaceous 
papules,	plaques,	nodules	or	tumors,	often	located	on	
trunk	and	 limbs,	 and	more	 rarely,	 in	head	and	neck	
region. 58,59	Secondary	anetoderma,	which	results	from	
the	destruction	of	cutaneous	elastic	fibers	and	is	often	
accompanied by the presence of anti-phospholipid an-
tibodies	in	the	serum,	is	more	frequently	observed	in	
PCMZL,	but	can	also	occur	in	PCFCL.61-64
Histological	 findings	 include	 non-epidermo-
tropic	nodular	or	diffuse	infiltrates,	consisting	of	small	
or	medium	 size	 lymphocytes,	with	 an	 indented	 nu-
cleus	and	a	pale	cytoplasm	(marginal	zone	B-cells	or	
monocytoid	B-cells),	and	relatively	abundant	lymph-
oplasmacytoid cells.65 Reminiscent reactive germinal 
centers,	often	colonized	by	B-cells	 tumor	and	mono-
clonal	(kappa	or	lambda+)	plasma	cells,	are	often	lo-
cated	 at	 the	 periphery	 of	 infiltrates.65,66	 In	 addition,	
aggregates of plasmacytoid cells are often present 
and these cells may exhibit cytoplasmic inclusions 
positive	for	periodic	acid-Schiff	(PAS),	commonly	re-
ferred to as “Dutcher bodies”. Cases with large num-
bers of lymphoplasmacytic cells and plasma cells with 
Dutcher bodies are designated as “cutaneous imuno-
cytomas”.35 There is also a variable number of reactive 
T-cells	and,	in	contrast	to	that	observed	in	most	other	
PCBCL,	aggregates	of	CD123+	plasmacytoid	dendritic	
cells	are	relatively	frequent.67
The	phenotype	of	B-cells	tumor,	documented	by	
immunohistochemical	studies,	includes	positivity	for	
CD19,	CD20,	CD22,	CD43,	CD79a,	BCL2	and	KiM1p	
(monocytoid	B-cells),	 and	negativity	 for	CD5,	CD10,	
CD23 and BCL6. In the reminiscent reactive germinal 
centers,	 B-cells	 do	 express	 CD10,	 BCL-6	 and	 BCL-2,	
and	plasma	cells	are	CD138+	and	CD79a+,	but	do	not	
express CD20.
In	 our	 experience,	 the	 immunophenotypic	
study	of	B	lymphocytes	that	infiltrate	the	skin,	by	flow	
cytometry,	 generally	 discloses	 a	 variable	 expansion	
of	monoclonal	 (kappa	 or	 lambda+),	 CD19+,	 CD20+,	
CD5-,	 CD10-	 B-cells,	 as	 well	 as	 a	 polyclonal	 B-cell	
background,	and	also	a	few	monoclonal	plasma	cells.
Analysis	of	IGH	gene	rearrangements	general-
ly shows a clonal pattern. 68 Some rare cases with t(18 
14)	 (q32,q21)	 (IGH/MALT1)	 and	 t(3;14)	 (p14.1;q32)	
(FOXP1/IGH)	have	been	described.69,70	However,	oth-
er	 chromosomal	 translocations	 found	 in	MALT	 lym-
phomas	 involving	MALT1	 genes	 -	 t(11;18)	 (q21,q21)	
(API2/MALT1)	and	t(14;18)	 (q32,q21)	 (IGH/MALT1)	
-	are	not	observed	in	PCMZL,	so	cytogenetic	studies	
have very limited value in the diagnosis.29,	71,72
Two	subtypes	of	PCMZL	were	proposed	based	
on having or not Ig heavy chain class switching: those 
with	 IgM	 expression	 (non-switched)	 and	 those	with	
IgG	 expression	 (switched).	 In	 IgG+	 cases,	 lymphoid	
infiltrate	 is	 often	 rich	 in	 T-cells	 (CD4>CD8),	 usually	
presenting	a	nodular	 infiltration	pattern.	B	cells	 typ-
ically	do	not	express	CXCR3,	and	an	increase	in	mast	
cells is uncommon. Extracutaneous disease manifes-
tations	are	also	rare.	In	contrast,	IgM+	cases	generally	
have	a	predominance	of	B-cells,	which	often	express	
CXCR3,	 and	extracutaneous	disease	 is	 relatively	 fre-
quent.73
Although	the	association	with	Borrelia burgdor-
feri infection has been described in single cases and 
series	of	patients	in	PCMZL	have	been	published,	doc-
umenting this association and leading to the hypothe-
sis of a pathogenic relationship between this infection 
and	the	development	of	lymphoma,	other	studies	did	
not support this hypothesis.13,15-18
Primary cutaneous follicle center B-cell lym-
phomas
Primary cutaneous follicle center B-cell lym-
phomas	 (PCFCL)	 originate	 from	 B-cells	 in	 the	 ger-
minal centers of lymphoid follicles and contribute 
to	about	10%	of	PCL.	Like	PCMZL,	they	have	an	ex-
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CharT 3: Main	characteristics	of	the	major	primary	cutaneous	B-cell	lymphomas	subtypes
Age
Sex
Skin lesions
Preferential location
Associated	conditions
Histopathology
Cytopathology
Immunohistochemistry
IGH rearrangements
Chromosomal transloca-
tions
Genes
Cutaneous relapse
Extracutaneous dissem-
ination
5-year survival rate
PCMZL
Adults	(sometimes	young)
F	=	M
Solitary	 or	 multiple	 reddish,	 dome-
shaped	 papules,	 nodules,	 or	 erythe-
matous	plaques
Trunk and limbs
Anetoderma	(some	cases)
Borrelia	burgdorferi	(some	cases)
Non-epidermotropic nodular or dif-
fuse	infiltrates
Small	 or	 medium	 size	 lymphocytes,	
with an indented nucleus and a pale 
cytoplasm	 (marginal	 zone	 B-cells	 or	
monocytoid	 B-cells),	 lymphoplasma-
cytoid	cells,	plasma	cells
CD20+,	CD79a+,
BCL2+,	BCL6-
MUM1-	(+	plasma	cells)
KiM1p+
CD10-
CD5-,	Cyclin	D1-
Clonal	in	the	majority	of	cases
t(14;18)	absent
Frequent
Very	rare
>	95%
PCFCL
Adults
F	=	M
Solitary or multiple nodules 
and/or	 tumors	 of	 firm	 con-
sistency,	non-ulcerated
Head and neck
-
Non-epidermotropic nodu-
lar	or	diffuse	infiltrates
Centrocytes,	with	some	cen-
troblasts and immunoblasts
CD20+,	CD79a+
BCL2-/+,	BCL6+
MUM1-
KiM1p-
CD10-
CD5-,	Cyclin	D1
Clonal
t(14;18)	present	in	some	cases
Frequent
Rare	(5	-	10%)
>	90%
PCDLBCL, leg type
Adults	(old	women+)
F	>	M
Solitary or multiple 
nodules and/or tu-
mors
Legs
-
Non-epidermotropic 
diffuse	infiltrates
Centroblasts or im-
munoblasts
CD20+,	CD79a+
BCL2+,	BCL6+/-
MUM1+
KiM1p-
CD10-
CD5-,	Cyclin	D1-
Clonal
t(14;18)	absent
t(9;21)	 present	 in	 the	
majority	of	cases
Losses in the 9p21 re-
gion	(CDKN2A	gene:	
proteins p16/INK4 
and	p14/ARF).
Gains in the 
18q21.31-q21.33	 re-
gion (BCL2 and 
MALT1	genes)
Frequent
Frequent
<	60%
Abbreviations: PCFCL,	primary	cutaneous	follicle	center	cell	lymphoma;	PCLBCL,	primary	cutaneous	large	B-cell	lymphomas,	leg	type;	;	PCMZL,	primary	cu-
taneous	marginal	zone	lymphomas;	F,	females;	M,	males;	BCL-2,	B-cell	lymphoma	2;	BCL-6,	B-cell	lymphoma	6;	MUM1/IRF4,	Multiple	Myeloma	1	/	Interferon	
Regulatory	Factor	4	protein;	INK4,	inhibitor	of	kinase	4),	CDK4,	cyclin	dependent	kinase	4;	ARF,	Alternate	open	Reading	Frame.	(*)	MUM1+	nos	plasma	cells.
An Bras Dermatol. 2015;90(5):687-706.
694 Lima M
cellent	prognosis,	with	a	 survival	 rate	 in	 5	years	 ex-
ceeding	90%;	likewise,	cutaneous	relapse	occurs	very	
commonly and extracutaneous dissemination is very 
rare.39,74	They	are	also	known	as	“Crosti’s	lymphomas”,	
in	honor	of	Crosti,	who	described	in	1951	a	number	of	
patients	with	 disfiguring	 erythematous	 plaques	 and	
nodules,	 giving	 it	 the	 designation	 of	 “reticulohistio-
cytoma”.75 In	 general,	 PCFCL	 manifests	 by	 nodules	
and/or	tumors	of	firm	consistency,	non-ulcerated,	 in	
the	head	and	neck	region,	but	may	also	occur	in	other	
body areas.39
From	 the	 histological	 point	 of	 view,	 three	
growth	 patterns	were	 described:	 follicular,	 follicular	
and	diffuse,	and	diffuse,	the	latter	being	the	most	com-
mon.	The	 lymphoid	 infiltrate	 is	 composed	primarily	
of	 cells	 with	morphology	 of	 centrocytes,	 with	 some	
centroblasts and immunoblasts. The sub-epidermal 
“Grenz	zone”	 is	 spared	 in	most	 cases.	 In	 contrast	 to	
that	 typically	 found	 in	 reactive	 lymphoid	 infiltrates,	
mitoses are rare observed and macrophages are rarely 
seen.76
Neoplastic	B	 lymphocytes	 are	CD19+,	CD20+,	
CD22+,	CD79a+,	CD5-,	CD23+/-,	CD43+,	BCL6+	and	
BCL2-/+.	CD10	 is	 expressed	predominantly	 in	 cases	
of follicular growth pattern. Expression of BCL2 is 
variable,	being	observed	in	less	than	half	of	the	cases,	
and	correlating	with	the	presence	of	t(14;18)	(q32,q21)	
and rearrangement of BCL2.76,77	MUM/IRF4	 antigen,	
which	is	positive	in	PCLBCL,	is	not	expressed	in	PCF-
CL and may be useful for differentiating these entities 
when a diffuse growth pattern is observed. The net-
work	of	CD21+	follicle	dendritic	cells	is	irregular.
From	a	molecular	standpoint,	 there	 is	a	clonal	
rearrangement of IGH genes. Unlike what happens 
in	 nodal	 follicular	 lymphoma,	 t(14;18)	 (q32,q21)	 and	
the corresponding BCL2 gene rearrangement is rarely 
observed.76,77	Cases manifesting in the legs and cases 
with	FOXP1	expression	seem	to	have	a	worse	progno-
sis and should be treated more aggressively.40
Primary cutaneous large B-cell lymphomas
Primary cutaneous large B-cell lymphomas 
(PCLBCL)	account	 for	 approximately	6%	of	 all	PCL.	
They have a more aggressive behavior and poorer 
prognosis	than	other	PCBCL,	with	a	survival	rate	in	5	
years	of	20-55%,	tending	to	spread	to	lymphnodes	and	
other extracutaneous sites.78-80 They are further classi-
fied	into	two	groups:	“leg	type”	and	“others”.
Primary cutaneous large B-cell lymphomas, 
leg type
PCLBCL-leg type usually manifests by nodules 
or	 tumors,	 single	 or	 multiple,	 localized	 in	 one	 ana-
tomic region. They are more common in older wom-
en	 and,	 as	 the	 name	 implies,	 skin	 lesions	 are	 more	
common in the legs. This type has a great tendency to 
relapse	as	well	as	to	spread	extracutaneously,	includ-
ing to regional lymph nodes. Location in the legs and 
existence	of	multiple	 lesions	were	 identified	as	poor	
prognostic factors in multivariate analysis. The lym-
phoma usually responds to treatment with R-CHOP 
(cyclophosphamide,	hydroxidoxorrubicin,	vincristine	
and	 prednisone	 +	 rituximab),	 but	 relapses	 are	 very	
common and treatment is not curative.
From	 the	histological	 point	 of	 view,	 there	 is	 a	
diffuse	 infiltrate	 composed	 of	 large	 lymphoid	 cells,	
with	 morphology	 of	 centroblasts	 or	 immunoblasts,	
occupying the dermis and extending to the subcuta-
neous	 tissue,	 the	 sub-epidermal	 zone	 being	 usually	
spared.78 Centrocytes	 and	 CD21+	 follicle	 dendritic	
cells,	which	 are	usually	 observed	 in	PCFCL,	 are	not	
present in PCLBCL. The characteristic immunophe-
notype	 is	 CD19+,	 CD20+,	 CD22+,	 CD79a+,	 BCL	 2+,	
MUM1+,	BCL6-/+,	CD5-,	CD10-,	CD138-,	and	Cyclin	
D1-. The strong positivity for BCL2 and MUM1 helps 
to differentiate these lymphomas from PCFCL with 
diffuse growth pattern.80
Molecular	studies	confirm	the	clonal	rearrange-
ment	of	the	IGH	gene	and,	despite	strong	expression	
of	BCL2,	t(14,18)	(q32,q21)	and	corresponding	BCL2/
JH rearrangement are not observed. 81 In	 addition,	
gene	expression	profile	differs	 from	that	observed	in	
PCFCL.33,34,82
Primary cutaneous large B-cell lymphomas, 
others
In	this	group	we	can	find	a	wide	variety	of	large	
B-cell	lymphomas	–	in	fact,	all	those	who	do	not	meet	
criteria for the diagnosis of PCLBCL-leg type.83-85 They 
are	intravascular	large	B-cell	lymphomas,	plasmablas-
tic	 lymphomas,	T-cell	and	histiocyte	rich	 large	B-cell	
lymphomas,	 and	CD30+	 anaplastic	 large	B-cell	 lym-
phomas,	among	others. 85-108 
Intravascular large B-cell lymphomas
Intravascular	large	B-cell	 lymphoma	(IVLBCL)	
is a subtype of large B-cell lymphoma that is charac-
terized	 by	 the	 accumulation	 of	 neoplastic	 B-cells	 in	
blood vessels. They often affect central nervous sys-
tem,	lungs	and	skin	and	generally	have	a	poor	prog-
nosis.85Although	 they	may	 be	 primary	 skin	 involve-
ment,	the	disease	is	usually	widespread.	Clinically	it	
manifests	as	purplish	patches	and	plaques	or	telangi-
ectatic	lesions,	often	located	on	legs	or	trunk.85 In some 
cases,	the	lymphoma	arises	in	cutaneous	angiomatous	
lesions.86,87	Prognosis is usually better in cases where 
the presentation is cutaneous than in cases with other 
forms	of	presentation	(survival	rate	in	3	years	of	56%	
versus	22%).85 From	the	histological	point	of	view,	di-
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lated	blood	vessels,	filled	by	neoplastic	 large	B-cells,	
are observed in dermis and subcutaneous tissue.85 
Treatment	 consists	 of	 chemotherapy,	 even	when	 the	
presentation is cutaneous.85
Other cutaneous large B-cell lymphomas
Plasmablastic lymphomas are aggressive lym-
phomas that usually occur in immunocompromised 
patients,	 particularly	 in	 HIV-infected	 patients	 and	
transplant	 recipients,	 and	 often	manifest	 in	 the	 oral	
cavity. They have been described to be associated with 
EBV	 and,	more	 recently,	with	HHV8.9,88-91	Neoplastic 
B-cells have a plasmablastic morphology and there 
is phenotypic evidence for terminal B-cell differentia-
tion,	with	frequent	positivity	for	CD38,	CD138,	MUM1	
and	EMA	(epithelial	membrane	antigen)	and	absence	
of expression of CD20 and CD79.9	2,93	As	in	malignant	
plasma	cells	from	patients	with	plasma	cell	myeloma,	
CD56	 is	 frequently	 aberrantly	 expressed	 in	 the	 neo-
plastic	 plasmablasts,	 and	 aberrant	 CD10	 expression	
may also be found.92 Only a few cases of cutaneous 
plasmablastic lymphomas were published.94-105 Most 
of	 them	 occurred	 in	 immunocompromised	 patients,	
either	 HIV	 infected	 or	 post-transplant,94 -101 although 
some cases also have been described in patients with-
out evidence of imunossupression.102-105
T-cell and histiocyte rich large B-cell lympho-
mas	 are	 rare	 (1-2%	of	 lymphomas),	 and	may	have	a	
nodal or extranodal presentation. Primary cutaneous 
forms	are	very	rare,	with	only	a	few	documented	cas-
es in the literature.106,	107	They	deserve	special	mention,	
as	neoplastic	B-cells	are	minimally	represented,	which	
can cause problems in diagnosis.
CD30+ anaplastic large B-cell lymphomas also 
deserve	special	attention,	since	they	have	not	been	in-
dividualized	as	an	independent	entity,	but	its	features	
seem	to	be	different.	A	retrospective	study	of	10	cases	
revealed	that	these	lymphomas,	which	have	an	excel-
lent	prognosis,	usually	manifest	as	single	skin	lesions,	
affect	 elderly	 individuals	 and	 are	 more	 frequent	 in	
women;	 in	addition,	 there	 is	quite	often	a	history	of	
previous treatment with methotrexate.108 Diagnosis is 
often	difficult	because	 reactive	T-cells	may	predomi-
nate,	 sometimes	with	a	granulomatous	reaction.	The	
neoplastic	B-cells	often	have	immunoblastic	features,	
and	 are	 positive	 for	 CD20,	 CD30,	 CD43	 and	 BCL2,	
with	frequent	EBV	infection.
STAGING
TNM	 classification	 used	 for	 PCTCL,	 mycosis	
fungoid	(MF)	and	Sezary	syndrome	(SS)	type,	revised	
in	2007,109 is not suitable for PCBCL. So in that same 
year,	 EORTC	 proposed	 a	 TNM	 system	 adapted	 for	
cutaneous	 lymphomas	 not	 MF/SS	 (Chart	 4).110 This 
scheme	 was	 subsequently	 validated	 by	 clinical	 and	
pathological	 studies,	 but	 it	 is	 complex	 and	 difficult	
to apply in clinical practice.39,40	Factors considered for 
staging	 include	 the	number	and	size	of	 skin	 lesions;	
the number of affected body regions and the fact that 
they are or are not contiguous; the number of nodal 
regions	involved	and	if	they	are	central	or	peripheral,	
draining or not skin areas affected by the lymphoma.
PROGNOSIS
In	general,	PCBCL	have	a	more	 indolent	clini-
cal course and a more favorable prognosis than their 
nodal counterparts. Tumor type and degree of cuta-
neous involvement are the most important prognostic 
factors.2,6,111
Overall	survival	rate	in	5	years	for	PCMZL	and	
PCFCL	 is	higher	 than	90%.	 In	contrast,	 for	PCLBCL,	
particularly	leg	type,	prognosis	is	more	guarded,	with	
a	survival	rate	 in	5	years	 lower	 than	60%.	 In	all	cas-
es,	cutaneous	recurrences	are	frequent,	but	in	PCMZL	
and in PCFCL types the disease usually remains local-
ized	to	the	skin,	while	in	PCLBCL,	especially	leg	type,	
extracutaneous dissemination is relatively common.
Given	the	good	prognosis,	patients	with	 indo-
lent	 PCMZL	 and	 PCFCL	 should	 be	 observed	 from	
the	 clinical	 point	 of	 view	 every	 6	 months,	 analysis	
and	 radiological	 examinations	being	 justified	only	 if	
there	is	evidence	of	disease	progression,	whereas	pa-
tients	with	PCLBCL	should	be	closely	monitored	(i.e.,	
monthly	or	quarterly).
TREATMENT
Treatment should be selected taking into ac-
count	the	type	of	lymphoma	and	its	stage,	and	should	
be adapted to risk. 4,7,112	(Chart	5)
Several therapeutic modalities are available 
for	PCBCL	 (Chart	6).56,113-142	However,	 indications	are	
based mainly on retrospective studies (case reports 
or	case	series),	with	notable	lack	of	randomized	con-
trolled trials that help to support clinical decisions. 
Generally,	 the	 consensus	 is	 that:	 a)	 aggressive	 treat-
ment	of	 indolent	PCBCL	(PCMZL	or	PCFCL)	should	
be	 avoided,	 as	 they	 have	 a	 very	 good	 prognosis;	 b)	
chemotherapy is indicated in PCLBCL-leg type and in 
patients	with	advanced	 forms	of	PCMZL	or	PCFCL,	
which are resistant to other treatments and/or have 
extracutaneous disease spread.
Treatment for indolent cutaneous B-cell lym-
phomas
In	patients	with	PCMZL	or	PCFCL,	treatment	is	
different as there is a single skin lesion or a small num-
ber	of	lesions	confined	to	one	region	or	two	adjacent	
regions,	or	where	there	are	multiple	skin	lesions.54,143-145	
In	 the	 first	 case,	 the	 options	 are	 surgical	 excision	 or	
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CharT 4: TNM	classification	for	cutaneous	lymphomas	non-Mycosis	Fungoid,	non-Sezary	Syndrome	proposed	
by the ISCL and the Cutaneous Lymphoma Task Force of the EORTC
CharT 5: Main treatment modalities for primary cutaneous B cell lymphomas
T	(tumor)†
N	(nodules)	††
M	(metastasis)
PCMZL
Radiotherapy,	 surgery,	 rituximab,	
IFN-alpha2a.
Polychemotherapy	(CHOP,	R-CHOP)	
reserved for patients with advanced 
and/or resistant cutaneous disease or 
extra-cutaneous involvement.
PCFCL
Radiotherapy,	 surgery,	 rituximab,	
IFN-alpha2a.
Polychemotherapy	(CHOP,	R-CHOP)	
reserved for patients with advanced 
and/or resistant cutaneous disease or 
extra-cutaneous involvement.
PCLBCL, leg type
Polychemotherapy	(CHOP,	R-CHOP).
Radiotherapy or surgery for solitary 
lesions,	IFN-alpha	or	rituximab	as	ad-
juvant	therapy	or	for	patients	unfit	for	
chemotherapy.
T1: Single cutaneous lesion
T1a:	Single	cutaneous	lesion	<5cm
T1b:	Single	cutaneous	lesion	>5cm
T2:	Regional	skin	involvement	(multiple	lesions	limited	to	one	region	or	two	contiguous	regions)
T2a:	All	lesions	–	Diameter:	<15cm
T2b:	All	lesions	–	Diameter:	15-30	cm
T2c:	All	lesions	–	Diameter:	>30cm
T3:	Generalized	skin	involvement
T3a: Multiple lesions involving 2 non-contiguous regions
T3b:	Multiple	lesions	involving	≥3	regions
N0: No clinical or pathologic LN involvement
N1: Involvement of one peripheral LN region that drains an area of current or prior skin involvement
N2: Involvement of two or more peripheral LN or involvement of any LN region that does not drain 
an area of current or prior skin involvement
N3: Involvement of central LN
M0:	No	evidence	of	extracutaneous	non–LN	disease
M1:	Evidence	of	extracutaneous	non–LN	disease
Definition of body regions (limits): Head	and	neck	(inferior	border—superior	border	of	clavicles,	T1	spinous	process);	Chest	(superior	border—superior	bor-
der	of	clavicles;	inferior	border—inferior	margin	of	rib	cage;	lateral	borders—mid-axillary	lines,	gleno-humeral	joints,	inclusive	of	axillae).	Abdomen	/	genital	
(superior	border—inferior	margin	of	rib	cage;	 inferior	border—inguinal	 folds,	anterior	perineum;	 lateral	borders—mid-axillary	 lines).	Upper	back	(superior	
border—T1	spinous	process;	inferior	border—inferior	margin	of	rib	cage;	lateral	borders—mid-axillary	lines).	Lower	back	/	buttocks	(superior	border—inferior	
margin	of	rib	cage;	inferior	border—inferior	gluteal	fold,	anterior	perineum,	inclusive	of	perineum;	lateral	borders—mid-axillary	lines).	Each	upper	arm	(supe-
rior	borders—glenohumeral	joints,	exclusive	of	axillae;	inferior	borders—ulnar/radial-humeral	/	elbow	joint).	Each	lower	arm/hand	(superior	borders—ulnar/
radial-humeral	/	elbow	joint.	Each	upper	leg,	thigh	(superior	borders—inguinal	folds,	inferior	gluteal	folds;	inferior	borders—mid-patellae,	mid-popliteal	fos-
sae).	Each	lower	leg,	foot	(superior	borders—mid-patellae,	mid-popliteal	fossae).
Definition of LN regions (Ann Arbor system): Peripheral	LN:	antecubital,	cervical,	supraclavicular,	axillary,	inguinal-femoral,	and	popliteal.	Central	LN:	me-
diastinal,	pulmonary	hilar,	paraortic,	iliac.
Abbreviations:	ISCL,	International	Society	for	Cutaneous	Lymphomas;	EORTC	European	Organization	of	Research	and	Treatment	of	Cancer.
Source:	Kim	YH	et	al,	2007 110
Abbreviations: PCMZL,	primary	cutaneous	marginal	zone	lymphomas;	PCFCL,	primary	cutaneous	follicle	center	cell	lymphoma;	PCLBCL,	primary	cutaneous	
large	B	cell	lymphomas;	IFN,	Interferon;	CHOP:	cyclophosphamide,	doxorubicin,	oncovin	(vincristine)	and	prednisone,	every	21	days,	6	-	8	courses;	R-CHOP,	
CHOP with rituximab.
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radiotherapy.	 In	 the	 second	 case,	 the	options	 consist	
mainly	of	 antibiotics,	monoclonal	 antibodies	 (mAbs)	
(i.e.,	 rituximab,	 an	 anti-CD20	 mAb)	 and	 interferons	
(i.e.	interferon	alpha	2a,	IFN-alpha2a).
Radiotherapy
In	 general,	 in	 patients	 undergoing	 radiation	
therapy,	cumulative	dose	per	field	ranges	from	15	Gy	
to	45	Gy,	generally	fractionated	into	doses	of	2	Gy	to	
2.5	Gy	per	irradiation	field	per	week,	and	usually	in-
cluding a margin of 1 cm to 5 cm of normal skin around 
the affected skin. Most of the patients have a complete 
response	(CR),	while	recurrence	occurs	in	about	half	of	
cases	(Table	1).54,80,115-118,145-150
A	retrospective	study	of	32	patients	with	PCBCL	
classified	according	to	the	EORTC	schema	–	PCFCL	(21	
cases;	66%);	PCMZL	(4	cases/	13%);	and	PCLBCL-leg	
type	 (3	 cases;	 9%)	 –	 treated	with	 local	 radiotherapy	
(median	dose:	40	Gy	ranging	from	20	Gy	to	48	Gy)	re-
vealed	 a	 100%	CR	 rate,	 an	overall	 survival	 rate	 in	 5	
years	of	96%	 (67%	 in	PCLBCL-leg	 type	and	100%	 in	
the	remaining	cases),	a	disease-free	survival	rate	in	5	
years	of	55%	(33%	in	patients	with	PCLBCL-leg	type	
and	from	62%	to	73%	in	other	types).	In	5	years,	21%	
of	patients	(33%	of	PCLBCL-leg	type)	had	extracuta-
neous disease.118
Another	retrospective	study	of	153	patients	with	
PCBCL	(101	with	PCFCL;	25	with	PCMZL;	and	27	with	
PCLBCL-leg	 type)	 treated	with	 radiotherapy	showed	
an	overall	response	(OR)	rate	of	100%	and	a	CR	rate	of	
99%,	with	rates	of	recurrence	of	60%,	29%	and	64%	for	
PCMZL,	PCFCL	and	PCLBCL,	respectively.149
Rituximab
Although	 published	 studies	 are	 all	 retrospec-
tive	and	therefore	uncontrolled	and	non-randomized,	
there seems to be evidence that rituximab induces last-
ing	remission	in	indolent	PCBCL	(PCMZL	or	PCFCL),	
without appreciable adverse events.151 Schemes for in-
travenous or intralesional administration of rituximab 
used	in	these	studies	were	relatively	similar,	with	some	
variations	in	dose	and	schedule	of	administration,	and	
total	number	of	doses	(Tables	2	and	3).120-131,152-159
Intravenous rituximab
A	 search	 via	 PubMed	 allowed	 identifying	 16	
papers	 published	 in	 journals	 indexed	 in	 MEDLINE	
between 2000 and 2013 that reported the use of intra-
venous	rituximab,	as	monotherapy	for	the	treatment	of	
CharT 6: Therapeutic schemas for cutaneous B-cell lymphomas
Therapy
Antibiotics
Local radiotherapy
Corticosteroids
Monoclonal antibodies
Immunomoduladors
Monochemotherapy
Monochemotherapy	+	
monoclonal antibodies
Polychemotherapy
Polychemotherapy	+	
monoclonal antibodies
Description
Doxicicline,	100	mg,	2xday,	3	weeks
Cefotaxime,	i.v.
Orthovoltage	 radiotherapy	 (20-100	 kV).	 Cumulative	 dose	 per	 irradiation	
field:	15	to	45	Gy	(2.0	to	2.5	Gy	/week,	fractionated).	Margins	ranging	from	
1 to 5 cm.
Corticosteroids,	intralesional
Rituximab,	 intralesional,	 2	 to	 3	 times	weekly,	 10	 to	 30	mg/dose/	 lesion,	
depending	on	the	size,	4	to	8	consecutive	weeks.
Rituximab,	i.v.,	375	mg/m2,	1x	week,	4	weeks.
Interferon	alpha	2a,	intralesional,	3	-	9	million	units,	3	x	week.
Peguilated	liposomal	doxorrubicin	(20-40	mg/m2,	i.v.,	every	2	to	4	weeks)
Peguilated	 liposomal	 doxorrubicin	 (20-40	mg/m2,	 i.v.,	 every	 2	 weeks)	 +	
rituximab	(375	mg/m2)
CHOP	 (cyclophosphamide,	 doxorrubicin,	 oncovin	 =	 vincristine	 e	
prednisone),	every	21	days,	6	courses
CHOP	+	rituximab
References
56
113
114-118; 146-149
119
120-124
125-131
132-136
137
138
80,	139
140-142
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Table 1: Radiotherapy for primary cutaneous B-cell lymphomas
Reference Number of Lymphoma classification  Response to treatment
 patients
  PCFCL PCMZL PCLBCL Other OR CR PR NR
146 35 (100%) 21(60%) 7(20%) 4(11%) 3(9%) 35(100%) 35(100%) 0(0%) 0(0%)
118 32(100%) 21(66%) 4(13%) 3(9%) 0(0%) 32(100%) 32(100%) 0(0%) 0(0%)
149 153(100%) 101(66%) 25(16%) 27(18%) 0(0%) 153(100%) 151(99%) 2(1%) 0(0%)
Total 220(100%) 143(65%) 36(16%) 34(15%) 3(1%) 220(100%) 218(99%) 2(1%) 0(0%)
Complementary 
information
Median follow-up 11 
months:	11	(31%)	relapses.
Median follow-up 52 
months,	 27	 (77%)	 alive;	 8	
(23%)	 death	 (3	 with	 lym-
phoma).
5-year	survival	rate:	75%.
Free disease 5-year surviv-
al	rate:	50%.
5-year survival rate: PCL-
BCL,	 leg	type	(67%);	other	
PCBCL	(100%).
Free disease 5-year sur-
vival:	 PCLBCL,	 leg	 type	
(33%);	other	PCBCL	(73%).
Follow-up	 5	 years:	 21%	
with extracutaneous dis-
ease
5-year survival rate: PCF-
CL	 (95%);	 PCMZL	 (97%);	
PCLBCL,	leg	type	(59%)
Relapse	 rate:	 PCMZL	
(60%);	PCFCL	(29%);	PCL-
BCL	 (64%);	 PCLBCL,	 leg	
type	(63%)
PCFCL with skin lesions in 
the	legs:	relapse	rate	(63%);	
5-year	survival	(44%)
PCFCL with skin lesions in 
other body regions: relapse 
rate	 (25%);	5-year	survival	
(99%)
Abbreviations:	PCBCL,	primary	 cutaneous	B-cell	 lymphoma;	PCFCL,	primary	 cutaneous	 follicle	 center	 cell	 lymphoma;	PCLBCL,	primary	 cutaneous	 large	
B-cell	lymphomas,	leg	type;	PCMZL,	primary	cutaneous	marginal	zone	lymphomas;	OR,	overall	response;	CR,	complete	response;	PR,	partial	response;	NR,	no	
response.
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Table 2: Intravenous rituximab for the treatment of primary cutaneous B-cell lymphomas
References Number of Lymphoma classification  Response to treatment
 patients 
  PCFCL PCMZL PCLBCL- PCLBCL,  OR CR PR NR
    leg type other
120 10 3 0 6 1 8 6 2 2
125 2 0 0 1 1 2 0 2 0
126 4 2 2 0 0 4 2 2 0
127 10 8 1 1 0 9 7 2 1
128 5 3 1 0 1 5 5 0 0
129 15 10 5 0 0 13 9 4 2
130 16 11 5 0 0 16 14 2 0
131 18 11 2 5 0 16 16 0 2
152 2 2 0 0 0 2 1 1 0
153 2 2 0 0 0 2 2 0 0
154 2 1 0 1 0 2 2 0 0
155 1 1 0 0 0 1 1 0 0
156 2 1 1 0 0 2 2 0 0
157 1 0 1 0 0 1 1 0 0
158 1 1 0 0 0 1 1 0 
159 11 11 0 0 0 11 7 4 0
Total 102 67 18 14 3 95 76 19 7
	 (100%)	 (66%)	 (18%)	 (14%)	 (3%)	 (93%)	(75%)	(19%)	(7%)
Complementary information
Maintenance therapy with rituximab 
every 4 weeks for 6 months
Median remission time: 23 months (4 - 
30	months).
Maintenance therapy with rituximab 
every 2 or 3 months in some patients. 
Follow-up: 17 - 66 months. One patient 
died in complete remission 66 months 
later; one patient developed a PCLBCL 
3 years later.
Median	times	of	follow-up,	time	to	re-
sponse,	duration	of	 response	and	 time	
to	progression:	36,	30,	24	e	24	months.
Five	 of	 the	 14	 patients	with	CR	 (35%)	
relapsed,	after	6	to	37	months
Mean follow-up time: 52 months. Re-
lapse	 81%	 of	 cases.	 Median	 time	 to	
relapse: 25 months. The patients that 
were refractory to rituximab had PCL-
BCL,	leg	type.
Disease progression after 6 and 17 
months,	respectively.
No relapses during a follow-up of 24 
and	17	months,	respectively.
No relapses during a follow-up of 18 
and	24	months,	respectively.
Relapse after 13 months.
Median follow-up time: 30 months (9 
-	65	months).	Relapse:	6	cases.	Median	
time to relapse: 23.6 months.
Rituximab	was	administered	intravenously,	375	mg/m2,	once	weekly,	4	to	8	consecutive	weeks.
Abbreviations:	PCBCL,	primary	 cutaneous	B-cell	 lymphoma;	PCFCL,	primary	 cutaneous	 follicle	 center	 cell	 lymphoma;	PCLBCL,	primary	 cutaneous	 large	
B-cell	lymphomas,	leg	type;	PCMZL,	primary	cutaneous	marginal	zone	lymphomas;	OR,	overall	response;	CR,	complete	response;	PR,	partial	response;	NR,	no	
response.
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Table 3: Intralesional rituximab for primary cutaneous B-cell lymphomas
References Number of Lymphoma classification  Response to treatment
 patients 
  PCFCL PCMZL PCLBCL- PCLBCL,  OR CR PR NR
    leg type other
120 2 1 0 1 0 2 0 2 0
121 3 3 0 0 0 3 3 0 0
122 2 0 2 0 0 2 2 0 0
123 1 1 0 0 0 1 1 0 0
124 35 18 17 0 0 33 25 8 2
153 7 3 4 0 0 7 6 1 0
156 6 3 3 0 0 6 6 0 0
Total 56(100%) 29(52%) 26(46%) 1(2%) 0(0%) 54(96%) 43(77%)  11(20%) 2(3%)
Complementary 
information
One patient repeated the 
treatment. Complete and 
prolonged	 response	 (>	 1	
year)	in	all	cases.
Follow-up time: 22 and 36 
months. Relapse in 1 case 
after 22 months.
No relapse at 6 months
Mean time to remission: 8 
weeks. Median follow-up 
time: 21 months. Medi-
an disease free time: 114 
months
Follow-up time: 12 to 27 
months. Relapse in 3/6 cas-
es	 (12,	 14	 and	 27	months,	
respectively).
Median follow-up time: 6 
months	(3-14	months).	Re-
lapse in 4/6 cases. Median 
time to relapse: 6 months
Rituximab	was	administered	intralesional,	10	to	30mg/lesion/session,	1	to	3	times	weekly,	4	to	8	consecutive	weeks	or	1	week	month,	4	to	8	eight	consecutive	
months.
Abbreviations:	PCBCL,	primary	 cutaneous	B-cell	 lymphoma;	PCFCL,	primary	 cutaneous	 follicle	 center	 cell	 lymphoma;	PCLBCL,	primary	 cutaneous	 large	
B-cell	lymphomas,	leg	type;	PCMZL,	primary	cutaneous	marginal	zone	lymphomas;	OR,	overall	response;	CR,	complete	response;	PR,	partial	response;	NR,	no	
response.
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PCBCL	in	a	total	of	102	patients	(Table	2).120,	125-131,152-159	In 
general,	the	dose	was	375	mg/m2/administration,	being	
repeated	weekly	 for	4	 to	8	weeks,	and	responses	were	
obtained	in	95	cases	(93%),	with	CR	in	76	cases	(75%).
Intralesional rituximab
Another	 search	via	PubMed	revealed	7	papers	
published	 in	 journals	 indexed	 in	MEDLINE	between	
2000	and	2012,	 in	which	rituximab	was	administered	
intralesional	 for	 the	 treatment	of	PCBCL	 (Table	 3).120-
124,153,156	In	total,	56	patients	were	treated	with	rituximab	
monotherapy	 (26	 patients	 with	 PCMZL,	 19	 patients	
with	 PCFCL	 and	 1	 patient	 with	 PCLBCL).	 Dose	 (in	
general,	 10	mg	 to	 30	mg	/lesion/session,	depending	
on	the	size	of	the	lesion),	frequency	of	administration	
(usually	 1	 to	 3	 times	 a	week)	 and	 intervals	 between	
them (usually 4 to 8 consecutive weeks or 1 week per 
month	for	4	to	8	months)	were	variable.	Fifty-four	cas-
es	(96%)	responded	to	treatment,	with	CR	in	43	cases	
(77%).
Adverse events
In	 general,	 rituximab	 is	 well	 tolerated.	 Local	
adverse effects reported after intralesional administra-
tion	 include,	 in	addition	 to	pain	at	 the	 injection	site,	
other	rare	manifestations	such	as	rash,	pruritus,	urti-
caria,	bacterial	infections,	lichenoid	reactions,	parane-
oplastic	 pemphigus,	 toxic	 epidermal	 necrolysis	 (Ste-
vens-Johnson	syndrome)	and	bullous	dermatitis.	Rare	
cases of urticaria reaction at lymphoma lesion were 
also reported after intravenous administration of rit-
uximab.120,155	Systemic events include anaphylactic re-
actions	and	reactivation	of	viral	 infections,	 including	
hepatitis	B,	arrhythmias,	vasculitis,	mucositis,	arthral-
gia and arthritis.160-164
Interferon alpha 2a
Interferon-alpha2a,	a	cytokine	capable	of	mod-
ulating the progression of the cell cycle and induce 
apoptosis	 with	 a	 significant	 anti-tumor	 activity,	 has	
been successfully used in the treatment of PCTCL and 
can be considered as a potential therapeutic alterna-
tive for PCBCL.165,166	However,	 there	 are	 only	 a	 few	
published studies on the use of IFN-alpha2a for treat-
ment of PCBCL.
Intralesional interferon alfa 2a
A	 search	 via	 PubMed	 revealed	 only	 5	 papers	
published	in	 journals	indexed	in	MEDLINE	between	
1989	 and	 2006,	 reporting	 on	 the	 use	 of	 intralesional	
IFN-alfa2a for the treatment of 12 patients with PCB-
CL,	most	of	them	PCMZL,	and	a	CR	was	obtained	in	
all	cases	(Table	4).132-134,136	The dose ranged from 3 to 9 
million/ units/ session and the sessions were repeat-
ed	3	times	a	week	for	several	months,	 in	some	cases	
for 1 year.
Subcutaneous interferon-alpha2a
Reports on the use of subcutaneous IFN-alpha2a 
for	the	treatment	of	PCBCL	are	even	more	scarce,	with	
only a few cases reported.167-169 In	 our	 experience,	
which is based on the treatment of 6 patients with PC-
MZL	of	whom	only	2	 cases	were	 targeted	 for	publi-
cation,	PCMZL	respond	well	 to	 IFN-alpha2a	admin-
istered	subcutaneously	at	a	dose	of	3	million	units,	3	
times	a	week,	until	maximum	response,	which	usually	
happens	after	a	variable	time	(median:	6	months).167,169	
Complete	response	was	observed	in	all	patients,	with	
a median duration of remission of 9 months. Relaps-
es	were	 frequent,	occurring	 in	50%	of	cases.	Patients	
with recurrence repeated treatment with IFN-alfa2a 
successfully.	 A	 case	 of	 a	 patient	 with	 PCFCL	 who	
achieved complete response after being treated with 
IFN-alpha2a	administered	subcutaneously,	4.5	million	
units,	3	times	a	week,	was	recently	published.168
Treatment for aggressive cutaneous B-cell 
lymphomas
Patients	 with	 PCLBCL,	 particularly	 leg	 type	
–	which	 have	more	 aggressive	 clinical	 behavior	 and	
poor	 prognosis	 –	 are	 candidates	 to	 treatment	 with	
multidrug	 therapy	 with	 CHOP	 (cyclophosphamide,	
doxorubicin,	 vincristine,	 and	 prednisone)	 or	 CHOP-
like regimens. 80,139	 In	 elderly	 patients,	 it	 should	 be	
advisable to reduce the doses of doxorubicin (25 mg/
m2),	 vincristine	 (1	 mg/m2)	 and	 cyclophosphamide	
(400 mg/m2)	with	the	goal	of	having	less	cardiac	and	
hematological toxicity.142 The association of rituximab 
to	the	chemotherapy	(e.g.	R-CHOP)	appears	to	result	
in	increased	benefit	compared	to	chemotherapy	alone,	
evaluated by the increase in the survival time.140 Rit-
uximab monotherapy leads to response rates lower 
than	those	observed	with	chemotherapy,	and	relapse	
appears	to	occur	earlier,	but	can	be	used	for	palliative	
treatment.141
Pegylated liposomal doxorubicin used success-
fully in the treatment of PCTCL in a dose from 20 mg/
m2 to 40 mg/m2,	 administered	 intravenously	and	re-
peated	every	2	to	4	weeks,	may	be	considered	an	alter-
native for the treatment of PCBCL having been used 
alone	or	 in	combination	with	rituximab,	with	appre-
ciable	response	rates,	good	tolerance	and	low	hemato-
logical toxicity.137-139
A	study	in	which	5	patients	with	PCBCL	(1	with	
PCMZL	and	4	with	PCLBCL-leg-type)	with	dissemi-
nated	skin	lesions)	were	treated	with	pegylated	lipo-
somal doxorubicin at a dose of 20 mg/m2 showed CR 
in	100%	of	cases.137 In	follow-up,	one	patient	died	with	
disease progression and 4 patients maintained CR af-
ter	5,	52,	63	and	69	months,	respectively.
Another	recent	study	in	which	12	patients	PCL-
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BCL were treated with pegylated liposomal doxoru-
bicin (20 mg/m2	 on	 days	 1	 and	 15)	 associated	with	
rituximab (375 mg/m2)	 showed	response	 in	10	of	12	
patients	 (8	 CR	 and	 2	 PR)	 -	 2	 out	 of	 3	 patients	with	
PCLBCL-leg type. Two patients relapsed at 31 and 32 
months,	respectively.138
A	relatively	common	side	effect	associated	with	
the	 administration	 of	 liposomal	 doxorubicin,	 which	
may	 also	 arise	 with	 other	 chemotherapy	 regimens,	
Table 4: Intralesional interferon alpha 2a for primary cutaneous B-cell lymphomas
References Number of Lymphoma classification  Response to treatment
 patients 
  PCFCL PCMZL PCLBCL- PCLBCL,  OR CR PR NR
    leg type other
132 1 0 0 0 1 1 1 0 0
133 1 0 1 0 0 1 1 0 0
134 1 0 0 0 1 1 1 0 0
135 1 0 1 0 0 1 1 0 0
136 8 0 8 0 0 8 8 0 0
Total 12(100%)	 0(0%)	 10(83%) 0(0%) 2(17%)	 12(100%) 12(100%)	 0(0%)	 0(0%)
Complementary 
information
One patient with PCLBCL 
(transformation of an indo-
lent	 PCBCL)	 refractory	 to	
chemotherapy
One	 patient	 with	 PCMZL	
associated to Borrelia burg-
dorferi infection resistant 
treatment of cefotaxime
One patient with T-cell rich 
PCLBCL
One	patient	with	PCMZL,	
stage	IVa
Eight patients with PCM-
ZL.	 Median	 time	 to	 com-
plete response: 8.5 weeks 
(3	 to	 20	 weeks).	 Relapses	
in	 2	 cases,	 after	 4	 and	 12	
weeks,	respectively
Interferon	alpha-2a	was	administered	intralesional,	3	to	9	millions	of	units,	3	times	weekly,	during	several	months.
Abbreviations:	PCBCL,	primary	 cutaneous	B-cell	 lymphoma;	PCFCL,	primary	 cutaneous	 follicle	 center	 cell	 lymphoma;	PCLBCL,	primary	 cutaneous	 large	
B-cell	lymphomas,	leg	type;	PCMZL,	primary	cutaneous	marginal	zone	lymphomas;	OR,	overall	response;	CR,	complete	response;	PR,	partial	response;	NR,	no	
response.
is	 the	 palmoplantar	 erythrodysesthesia,	 also	 known	
as	 “hand-foot-syndrome”,	which	 is	 characterized	 by	
painful	 acral	 (palmoplantar)	 erythema.170-172 Coldness 
during	 administration	 of	 chemotherapy,	 topical	 ap-
plication of high potency corticosteroids and prophy-
lactic administration of pyridoxine orally are some of 
the recommended measures to control the associated 
symptoms.172 q
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